ISRG Research Update — June 20, 2026
Updated Thesis
Intuitive Surgical is a leading healthcare company specializing in robotic surgical systems, instruments, and accessories with a very wide competitive moat supported by over 80% global market share in installed systems and procedures. The company benefits from high recurring revenue streams driven by procedure volume and installed base utilization, with instruments and accessories generating $6.02 billion in 2025 revenue growing 19% year-over-year and systems revenue of $2.47 billion growing 26% year-over-year. Despite a premium valuation with a trailing and forward P/E of 48.6 and P/S of 13.61, the stock is fairly priced relative to its five-year history and growth prospects, with a fair value estimate of $589.83 implying 45% upside.
The investment grade as of this refresh is B — solid business quality. High-tier business, mid-tier valuation
Key Metrics at a Glance
- Revenue growth: +23.0% year over year
- Net margin: 28.2%
- Forward P/E: 48.6x
- Fair value upside: +45.0% to our estimate of $590
Current price: $406.78
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Intuitive Surgical, Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full ISRG research →](/stocks/ISRG)